A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
Public ClinicalTrials.gov record NCT00352742. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to describe the safety and effect of ATN-224 in combination with bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory to bortezomib.
Study identification
- NCT ID
- NCT00352742
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2006
- Primary completion
- Aug 31, 2008
- Completion
- Nov 30, 2008
- Last update posted
- Oct 27, 2008
2006 – 2008
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hematolgy-Oncology Medical Group of Fresno, Inc. | Fresno | California | 93720 | — |
| Institute for Myeloma and Bone Cancer Research | West Hollywood | California | 90069 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Billings Clinic | Billings | Montana | 59101 | — |
| The Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| SUNY Downstate | Brooklyn | New York | 11203 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Mary Crowley Medical Research Center | Dallas | Texas | 75246 | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00352742, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2008 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00352742 live on ClinicalTrials.gov.